Oklahoma City Oklahoma Clinical Trials

Logitudinal Study of Patients With Opioid-Induced Constipation
The main objective of the study is to calculate the rate of inadequate response to laxatives in a cohort of patients with OIC, as well as to gain a detailed understanding of the burden of illness of OIC by documenting the characteristics of patients [more...]  seeking usual care in the laxative-inadequate responders (LIR) and the laxative-adequate responders (LAR) opioid user subgroups. The study will do so by evaluating the burden of illness impact of OIC on each of the opioid user patient sub-groups of interest in terms of clinical outcomes (including symptoms), resource utilization (laxative use, OIC-related MD visits, hospitalizations, and ER visits), economic burden, and HRQL. This study also aims to identify "predictors" of outcomes of interest and will evaluate physician and patient perceptions of the severity and burden of OIC.
Status: Recruiting Start Date: October 2012 Completion Date: January 2014
OCAST Smoking Intervention Study
The long-term gaol is to improve the quality of life of children and their parents who smoke tobacco by facilitating parental smoking cessation in a way that is easy to administer yet effective. We aim to accomplish this goal by administering an interactive computer-based [more...]  program that will facilitate motivation and readiness to engage in smoking cessation by providing personalized feedback about the financial and health effects of the parent's smoking. We will compare the changes in motivation and readiness to quit smoking after the parent has taken the computer-based program and compare them to the changes in motivation and readiness to quit in parents who receive only information about the Oklahoma Tobacco Helpline. We will also measure salivary cotinine levels in both parents and children, to objectively measure changes in smoking habits and secondhand smoke exposure. Our hypothesis is that our computer-based program will cause a greater increase in motivation and confidence to quit smoking in the group that receives the customized feedback than the group that receives only information about the Tobacco Helpline. We also predict that both parent and child cotinine levels will show a greater decrease in the group randomized to receive personalized feedback.
Status: Recruiting Start Date: July 2013 Completion Date: 
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
Status: Recruiting Start Date: July 2013 Completion Date: December 2013
Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
A prospective, randomized, open label, multi-center, parallel group, 3-arm phase III study comparing the efficacy and safety of both, LGX818 plus MEK162 and LGX818 monotherapy, as compared to vemurafenib in patients with locally advanced unresectable or metastatic melanoma with [more...]  BRAF V600 mutation. A total of approximately 900 patients will be randomized 1:1:1 to one of 3 treatment arms: 1) LGX818 plus MEK162 (denoted as Combination arm), 2) LGX818 monotherapy (denoted as LGX818 arm), 3) vemurafenib.
Status: Recruiting Start Date: September 2013 Completion Date: June 2017
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of MS who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary [more...]  objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.
Status: Recruiting Start Date: July 2013 Completion Date: July 2015
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
XLPAD is an observational study designed to evaluate the effectiveness and use of stent and non-stent based therapies among PAD patients. The study will create a registry that will include entry of procedural and clinical follow-up information into an online data [more...]  collection software, REDCAP. The primary objectives of this observational registry study are to: 1. Compare stent and non-stent based outcomes defined as a composite of symptom driven target vessel revascularization (TVR), unplanned surgical revascularization of the target limb and need for target limb amputation through 12 months post-index procedure (Primary efficacy endpoint) 2. Compare stent and non-stent based outcomes defined as a composite of causes such as: death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel revascularization (TVR) and unplanned surgical revascularization/amputation of the target limb through 12 months (Primary safety endpoint) 3. Compare stent and non-stent based change in walking distance, Rutherford category and/or ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical improvement endpoint) Approximately 2,174 patients will be enrolled at approximately 20 sites worldwide. Enrollment in the observational study will be monitored in an effort to achieve at least 20% (and no more than 80%) of the population receiving stents as the initial treatment strategy. Follow-up visits by sites will be reported at 6 and 12 months after index procedure to collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures are not mandated by the registry protocol. Each site will be encouraged to enter follow-up information derived from clinically indicated follow-up visits. All events post-index procedure till the 7th month will be reported under the 6 month follow-up form and subsequent follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. The procedural aspects (including selection of stent type or non-stent based treatments) and follow-up are not mandated by the registry and will be up to the discretion of the operator and/or based upon the practice dictated by the clinical care of the patient. Therefore the study poses minimal risk to the patient.
Status: Recruiting Start Date: January 2013 Completion Date: January 2033
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
To test the idea that solanezumab will slow the cognitive and functional decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Status: Recruiting Start Date: July 2013 Completion Date: December 2016
An Observational Study in Patients With Asthma Initiating Treatment With Xolair (Omalizumab)
This observational study will evaluate the correlation of patient's characteristics with predictive markers of clinical outcome in patient with moderate to severe asthma initiating treatment with Xolair (omalizumab). Data will be collected for 48 weeks.
Status: Recruiting Start Date: June 2013 Completion Date: November 2015
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
Status: Recruiting Start Date: June 2013 Completion Date: August 2015
CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
CARMELINA is a randomized, double-blind, placebo controlled, parallel group study and compares treatment with linagliptin (5 mg once daily) to treatment with placebo (matching tablets once daily) as add-on therapy to standard of care.
Status: Recruiting Start Date: July 2013 Completion Date: January 2018
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
Status: Recruiting Start Date: June 2013 Completion Date: August 2015
A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of GDC-0068 in combination with mFOLFOX6 chemotherapy in patients with advanced or metastatic gastric or gastroesophageal junction cancer. Patients will be randomized to receive either GDC-0068 or placebo orally [more...]  daily on Days 1-7 of each 14-day cycle in combination with mFOLFOX6 on Day 1 of each cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Status: Recruiting Start Date: June 2013 Completion Date: August 2015
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled, single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with persistent asthma. The primary purpose of this study is to compare the efficacy and safety of Albuterol Spiromax with that of [more...]  ProAir HFA in pediatric asthma patients at 2 delivered dose levels equivalent to 90 mcg and 180 mcg of albuterol base.
Status: Recruiting Start Date: July 2013 Completion Date: November 2013
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (DARWIN2)
- 280 patients suffering from active rheumatoid arthritis who have an inadequate response to methotrexate will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - [more...]  50mg, 100mg and 200mg once daily) or matching placebo for 24 weeks. - During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) will be determined. Also, the effects of different doses of GLPG0634 administration on subjects' disability, fatigue and quality of life will be evaluated.
Status: Recruiting Start Date: July 2013 Completion Date: January 2015
A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in patients with basal cell carcinoma. Patients will be randomized to receive oral daily doses of vismodegib 150 mg or matching placebo. The [more...]  anticipated time on study drug treatment is 12 weeks.
Status: Recruiting Start Date: June 2013 Completion Date: July 2015
The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects
The objectives of this study is - To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameters from baseline after 12 weeks of treatment. [more...]  - To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters
Status: Recruiting Start Date: July 2013 Completion Date: October 2014
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)
- 595 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50mg, 100mg and 200mg [more...]  daily -, each evaluated as QD and BID regimen) or matching placebo for 24 weeks. - During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) will be determined. Also, the effects of different doses and dose regiments of GLPG0634 administration on subjects' disability, fatigue, and quality of life will be evaluated.
Status: Recruiting Start Date: July 2013 Completion Date: February 2015
Novel Methods to Reduce Children's Secondhand Smoke Exposure II
The overall aim of the current study is to determine if the use of nicotine containing products by caregivers who smoke and who are not interested in quitting, is effective in reducing children's secondhand smoke exposure.
Status: Recruiting Start Date: June 2013 Completion Date: 
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
Status: Recruiting Start Date: September 2013 Completion Date: 
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides for 2 years of additional treatment with baricitinib, [more...]  but may be extended to allow for continued treatment for up to 5 years after evaluation of the safety profile of baricitinib.
Status: Recruiting Start Date: June 2013 Completion Date: June 2020
Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know [more...]  which group each is in.
Status: Recruiting Start Date: June 2013 Completion Date: June 2014
Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee
The aim of this study is to evaluate the effectiveness and safety of a combined Traumeel® /Zeel® injection against placebo in patients with moderate-to-severe pain associated with osteoarthritis of the knee.
Status: Recruiting Start Date: June 2013 Completion Date: January 2014
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCGRRx in combination with metformin versus placebo + metformin
Status: Recruiting Start Date: July 2013 Completion Date: February 2015
[1] 2 3 4 Next >>

 

Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.

Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.

Oklahoma City Oklahoma Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Oklahoma City Oklahoma. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Oklahoma City Oklahoma studies are federally regulated with strict guidelines to protect patients.

Latest Clinical
Trials News
Diabetes Clinical Trials search for new treatments and cures
03/14/2010

There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.

Feeling Depressed? A clinical trial might help.
03/07/2010

There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.

The State of Constipation Clinical Trials
02/28/2010

Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.

view more...